{"organizations": [], "uuid": "97a1282e4bed85d064c33fb97f5f261ab83e1821", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-sees-us-n/brief-ironwood-pharmaceuticals-sees-u-s-net-sales-of-linzess-of-about-700-million-for-fy-ended-dec-31-2017-idUSFWN1P30TP", "country": "US", "domain_rank": 408, "title": "BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.554, "site_type": "news", "published": "2018-01-09T00:53:00.000+02:00", "replies_count": 0, "uuid": "97a1282e4bed85d064c33fb97f5f261ab83e1821"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-sees-us-n/brief-ironwood-pharmaceuticals-sees-u-s-net-sales-of-linzess-of-about-700-million-for-fy-ended-dec-31-2017-idUSFWN1P30TP", "ord_in_thread": 0, "title": "BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ironwood pharmaceuticals inc", "sentiment": "negative"}, {"name": "allergan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News January 8, 2018 / 4:53 PM / Updated 38 minutes ago BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Ironwood Pharmaceuticals Inc: \n* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017 \n* IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​ \n* IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017 \n* IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017 Source text : ( bit.ly/2CQ3Ise ) Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2CQ3Ise"], "published": "2018-01-09T00:53:00.000+02:00", "crawled": "2018-01-08T19:26:24.018+02:00", "highlightTitle": ""}